Funktion und klinische Bedeutung des Plasminogen-Aktivator-Inhibitors PAI-1 bei gynäkologischen Malignomen. Eine Übersicht

D. Könsgen; A. Mustea; W. Lichtenegger; J. Sehouli

doi:10.1055/s-2005-836407

Zentralblatt für Gynäkologie, Table of Contents

Zentralbl Gynakol 2005; 127(3): 125-131
DOI: 10.1055/s-2005-836407

Übersicht

Funktion und klinische Bedeutung des Plasminogen-Aktivator-Inhibitors PAI-1 bei gynäkologischen Malignomen. Eine Übersicht[*]

Role of PAI-1 in Gynaecological MalignanciesD. Könsgen¹ , A. Mustea¹ , W. Lichtenegger¹ , J. Sehouli¹

¹Klinik für Frauenheilkunde und Geburtshilfe, Campus Virchow-Klinikum, Charité Universitätsmedizin Berlin

Abstract

Zusammenfasssung

Der sog. Plasminogen-Aktivator-Inhibitor PAI-1 steht in den letzten Jahren zunehmend im Fokus der gynäkologischen Onkologie. Der vorliegende Beitrag beleuchtet zum einen die physiologischen und pathophysiologischen Zusammenhänge und diskutiert zum anderen den prognostischen Stellenwert des PAI-1 bei verschiedenen gynäkologischen Malignomen.

Abstract

The plasminogen activator-plasmin cascade plays a central role in tumor cell invasion and metastasis of solid tumors. The type-1 plasminogen activator inhibitor (PAI-1) is the major physiologic regulator of the plasminogen activation. The PAI-1 is suggested to play a crucial role in tumor cell invasion and metastasis of different solid tumors. The aim of this article is to give an overview of the function, clinical and prognostic role of PAI-1 in gynaecological malignancies.

Schlüsselwörter

PAI-I - Ovarialkarzinom - gynäkologische Malignome

Key words

PAI-1 - ovarian cancer - gynaecological malignancies

Full Text

References

Literatur

1 Andreasen P A, Georg B, Lund L R, Riccio A, Stacey S N. Plasminogen activator inhibitors: hormonally regulated serpins. Mol cell Endocrinol. 1990; 68 1-19
2 Andreasen P A, Kjoller L, Christensen L, Duffy M J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997; 72 1-22
3 Astedt B, Holmberg L. Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature. 1976; 261 595-597
4 Berger D H. Plasmin/Plasminogen System in Colorectal Cancer. World J Surg. 2002; 26 767-771
5 Bouchet C, Hacene K, Martin P M, Becette V, Tubiana-Hulin M, Lasry S, Oglobine J, Spyratos F. Dissemination risk index based on plasminogen activator system components in primary breast cancer. J Clin Oncol. 1999; 17 3048-3057
6 Cantero D, Friess H, Deflorin J. et al . Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Thromb Haemost. 1997; 77 62-70
7 Chambers S K, Ivins C M, Carangiu M L. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer. 1998; 79 449-454
8 Choong P FM, Anne P W. Urokinase Plasminogen activatot System. A multifunctional role in tumor progression and metastasis. Clin Orthop Rel Res. 2003; 415 (Suppl) 46-58
9 Cubellis M V, Wun T C, Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by ist specific inhibitor PAI-1. EMBO J. 1990; 9 1079-1085
10 Danri-Navarro A, Macias-Lopez G, Oceguera-Villanueva A, Del Toro-Arreola S, Bravo-Cuellar A, Perez-Montfort R, Orbach-Arbouys S. Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions. Eur J Cancer. 1998; 34 566-569
11 De Bruin P A, Griffioen G, Verspaget H W. et al . Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res. 1988; 48 4520-4524
12 Deng G, Royle G, Seiffert D, Loskutoff D J. The PAI-1/vitronectin interaction: two cats in a bag?. Thrombosis Haemostasis. 1995; 74 66-70
13 Donate L E, Gherardi E, Srinivasav N, Sowdhamini R, Aparicio S, Blundell T L. Molecular evolution and domain structure of plasminogen-related growth factors (HGF/SF and HGF1/MSP). Protein Sci. 1994; 3 2378-2394
14 Duffy M J, O'Grady P, Devaney D, O'Siorain L, Fennelly J J, Lijnen H J. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer. 1988; 62 531-533
15 Duval-Jobe C, Parmely M J. Regulation of plasminogen activation by human U937 promoocytic cells. J biol Chem. 1994; 269 21 353-21 357
16 Eppenberger U, Kueng W, Schlaeppi J M, Roesel J L, Benz C, Mueller H, Matter A, Zuber M, Luescher K, Litschgi M, Schmitt M, Foekens J A, Eppenberger-Castori S. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol. 1998; 16 3129-3136
17 Ferno M, Bendahl P O, Borg A, Brundell J, Hirschberg L, Olsson H, Killander D. Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. Europ J Cancer. 1996; 32 793-801
18 Foekens J A, Peters H A, Look M P, Portengen H, Schmitt M, Kramer M D, Brunner N, Janicke F, Meijer-van Gelder M E, Henzen-Logmans S C, Putten W L, van Klijn J G. The urokinase system of plasminogen activation and prognosis in 2 780 breast cancer patients. Cancer Res. 2000; 60 636-643
19 Foekens J A, Schmitt M, van Putten W L, Peters H A, Kramer M D, Janicke F, Klijn J G. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol. 1994; 12 1648-1658
20 Fredstorp-Lidebring M, Bendahl P O, Brunner N, Casslen B, Hogberg T, Langstrom-Einarsson E, Willen R, Ferno M. Urokinase plasminogen activator and ist inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer. Eur J Cancer. 2001; 37 2339-2348
21 Fujimoto J, Hori M, Ichigo S, Hirose R, Sakaguchi H, Tamaya T. Comparative study on expression of plasminogen activator inhibitor 1 and its mRNA in endometrial cancers and normal endometria. Tumour Biol. 1997; 18 13-21
22 Ginsburg D, Zeheb R, Yang A Y, Rafferty U M, Andreasen P A, Nielsen L, Dano K, Lebo R V, Gelehrter T D. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest. 1986; 78 1673-1680
23 Gleeson N C, Gonsalves R, Bonnar J. Plasminogen activator inhibitors in endometrial adenocarcinoma. Cancer. 1993; 72 1670-1672
24 Grondahl-Hansen J, Christensen I J, Rosenquist C, Brunner N, Mouridsen H T, Dano K, Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 1993; 53 2513-2521
25 Hapke S, Kessler H, Arroyo de Prada N, Benge A, Schmitt M, Lengyl E, Reuning U. Integrin αvβ/Vitronectin Interaction affects expression of the urokinase System in human ovarian cancer cells. J Biol Chem. 2001; 276 26 340-26 348
26 Harbeck N, Alt U, Berger U, Kates R, Krüger A, Thomssen C, Jänicke F, Graeff H, Schmitt M. Long-term follow-up confirms prognostic impact of PAI-1 and cathepsins D and L in primary breast cancer. Int J Biol Markers. 2000; 15 79-83
27 Harbeck N, Kates R E, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol. 2002; 20 1000-1007
28 Harbeck N, Schmitt M, Kate R E, Kiechle M, Zemzoum I, Jänicke F, Thomssen C. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1. Determination in primary breast cancer tissue for individualized therapy concepts. Clinical Breast Cancer. 2002; 3 196-200
29 Hazelbag S, Kenter G G, Gorter A, Fleuren G J. Prognostic relevance of TGF-beta 1 and PAI-1 in cervical cancer. Int J Cancer. 2004; 112 1020-1028
30 Herszenyi L, Plebani M, Carraro P. et al . The role of cysteine and serine proteases in colorectal carcinoma. Cancer. 1999; 86 1135-1142
31 Hoffmann G, Casper F, Weikel W, Kummerl T, Pollow B, Schaffrat M, Hoffmann M, Pollow K. Value of p53, urokinase plaminogen activator, PAI-1 and Ki-67 in vulvar carcinoma. Zentralbl Gynakol. 1999; 121 473-478
32 Hoffmann G, Pollow K, Weikel W, Strittmatter H J, Bach J, Schaffrath M, Knapstein P, Melchert F, Pollow B. Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters. Clin Chem Lab Med. 1999; 37 47-54
33 Horn L C, Pippig S, Raptis G, Fischer U, Kohler U, Hentschel B, Martin R. Clinical relevance of urokinase-type plasminogen activator and ist inhibitor type 1 (PAI-1) in squamous cell carcinoma of the uterine cervix. Aust N Z J Obstet Gynaecol. 2002; 42 383-386
34 Jänicke F, Prechtl A, Thommsen C. et al . Randomized adjuvant therapy trial in high-risk lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type-1. J Natl Cancer Inst. 2001; 93 913-920
35 Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H. Urokinase plasminogen activator (u-PA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat. 1993; 24 195-208
36 Kim S J, Shiba E, Kobayashi T, Yayoi E, Furukawa J, Takatsuka Y, Shin E, Koyama H, Inaji H, Takai S. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin Cancer Res. 1998; 4 177-182
37 Klinger K W, Winqvist R, Riccio A, Andreasen P A, Sartorio R, Nielsen L S, Stuart N, Stanislovitis P, Watkins P, Douglas R, Grzeschik K H, Alitalo K, Blasi F, Dano K. Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci USA. 1987; 84 8548-8552
38 Knoop A, Andreasen P A, Andersen J A, Hansen S, Laenkholm A V, Simonsen A C, Andersen J, Overgaard J, Rose C. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer. 1998; 77 932-940
39 Kobayasi H, Fujishiro S, Terao T. Impact of urokinase type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res. 1994; 54 6539-6548
40 Köhler U, Hiller R, Martin D. et al . Tumor-associated proteolytic factors uPA and PAI-1 in endometrial carcinoma. Gynecol Oncol. 1997; 66 268-274
41 Konecny G, Untch M, Pihan A, Kimmig R, Gropp M, Stieber P, Hepp H, Slamon D, Pegram M. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clinical Cancer Research. 2001; 7 1743-1749
42 Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Jänicke F, Graeff H. Urokinase (u-PA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol. 1994; 55 401-409
43 Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, Harbeck N, Spathe K, Dettmar P, Hofler H, Janicke F, Schmitt M, Graeff H. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer. 1999; 79 1746-1751
44 Kute T E, Grondahl-Hansen J, Shao S M, Long R, Russell G, Brunner N. Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat. 1998; 47 9-16
45 Lauffenburger D. Making connections count. Nature. 1996; 383 390-391
46 Liotta L A, Steeg P S, Stetler-Stevenson W G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991; 64 327-336
47 Liu G, Shuman M A, Cohen R L. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer. 1995; 60 501-506
48 Look M P, van Putten W LJ, Duffy M J. et al . Pooled analysis of prognostic impact of u-PA and PAI-1 in 8 377 breast cancer patients. J Natl Cancer Inst. 2002; 94 116-128
49 Murphy G, Stanton H, Cowell S. et al . Mechanisms for pro matrix metalloproteinases activation. APMIS. 1999; 107 38-44
50 Naldini L, Vigna E, Bardelli A. et al . Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by stoichiometric reaction. J Biol Chem. 1995; 270 603-611
51 Nekarda H, Siewert J, Schmitt M and Ulm K. Tumor-associated proteolytic factors u-PA and PAI-1 and survival in totally resected gastric cancer. Lancet. 1994; 343 117
52 Nykjaer A, Conese M, Christensen E I, Olson D, Cremona O, Gliemann J, Blasi F. Recycling of the urokinase receptor upon internalization of uPA: Serpin complexes. EMBO J. 1997; 16 2610-2620
53 Oka T, Ishida T, Nishino T, Sugimachi K. Immunhistochemical evidence for urokinase plasminogen activator in primary and metastatic tumors of pulmonary carcinoma. Cancer Res. 1991; 51 3522-3525
54 Park J E, Keller G A, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell. 1993; 4 1317-1326
55 Pedersen H, Grondahl-Hansen J, Francis D, Osterlind K, Hansen H H, Dano K, Brünner N. Urokinase and plasminogen activator inhibitor type-1 in pulmonary adenocarcinoma. Cancer Res. 1994; 54 120-123
56 Pujade-Lauraine E, Lu H, Mirshahi S, Soria J, Soria C, Bernadou A, Kruithof E KO, Lijnen H R, Burtin P. The plasminogen-activation system in ovarian tumors. Int J Cancer. 1993; 55 27-31
57 Riethdorf L, Riethdorf S, Petersen S, Bauer M, Herbst H, Janicke F, Loning T. Urokinase gene expression indicates early invasive growth in squamous cell lesions of the uterine cervix. J Pathol. 1999; 189 245-250
58 Saito K, Nagashima M, Itawa M. et al . The concentration of tissue plasminogen activator and urokinase in plasma and tissue of patients with ovarian and uterine tumors. Thromb Res. 1990; 58 355-366
59 Schmalfeldt B, Kuhn W, Reuning U, Pache L, Dettmar P, Schmitt M, Jänicke F, Höfler H, Graeff H. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res. 1995; 55 3958-3963
60 Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridmann R, Berger U, Schmitt M, Kuhn W, Lengyel E. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 2001; 7 2396-2404
61 Schmitt M, Harbeck N, Thomsson C. et al . Clinical impact of plasminogen activation system in tumour invasion and metastasis: Prognostic relevance and target for therapy. Thromb Haemost. 1997; 78 285-296
62 Sheng S. The urokinase-type plaminogen activator system in prostate cancer metastasis. Cancer and Metastasis Reviews. 2001; 20 287-296
63 Skelly M M, Troy A, Duffy M J. et al . Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome. Clin Cancer Res. 1997; 3 1837-1840
64 Stefansson S, Lawrence D A. The serpin PAI-1 inhibits cell migration by blocking intergrin αvβ3 binding to vitronectin. Nature. 1996; 383 441-443
65 Sweep C G, Geurts-Moespot J, Grebenschikov N, de Witte J H, Heuvel J J, Schmitt M, Duffy M J, Janicke F, Kramer M D, Foekens J A, Brunner N, Brugal G, Pedersen A N, Benraad T J. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer. 1998; 78 1434-1441
66 Taponeco F, Curcio C, Giuntini A, Nardini V, Fornaciari G, Artini P G, D'Ambrogio G, Genazzani A R. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer. J Exp Clin Cancer Res. 2001; 20 239-246
67 Tecimer C, Doering D L, Goldsmith L J, Meyer J S, Abdulhay G, Wittliff J L. Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer. Int J Gynecol Cancer. 2000; 10 372-381
68 Tecimer C, Doering D L, Goldsmith L J, Meyer J S, Abdulhay G, Wittliff J L. Clinical relevance of urokinase-type plasminogen activator, its receptor, its inhibitor type 1 in endometrial cancer. Gynecol Oncol. 2000; 80 48-55
69 Van der Burg M EL, Henzen-Logmans S C, Berns E MJJ, Putten W LJ, van Klijn J GM, Foekens J A. Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int J Cancer (Pred Oncol). 1996; 69 475-479
70 Vassalli J D, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol. 1985; 100 86-92
71 Wang S N, Miyauchi M, Koshikawa N. et al . Antigen expression associated with lymph node metastasis in gastric adenocarcinomas. Pathol Int. 1994; 44 844-849

1 Auszüge aus dem Manuskript wurden auf dem „1. Berliner Symposium: Molekularbiologie in der Gynäkologischen Onkologie - Quo vadis 2004” präsentiert

D. Könsgen

Klinik für Frauenheilkunde und Geburtshilfe · Campus Virchow-Klinikum · Charité Universitätsmedizin

10117 Berlin

Phone: 0 30/4 50 56 40 52

Fax: 0 30/4 50 56 49 52